The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study

EBioMedicine

Volumn 2, Issue 3, 2015, Pages 194-204

  Bunney, Tom D ^a   Wan, Shunzhou ^a   Thiyagarajan, Nethaji ^a   Sutto, Ludovico ^a   Williams, Sarah V ^b   Ashford, Paul ^a   Koss, Hans ^a,c   Knowles, Margaret A ^b   Gervasio, Francesco L ^a   Coveney, Peter V ^a   Katan, Matilda ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Cancer; Clinical inhibitors; FGFR; Resistance mutations

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN KINASE;

ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CELL VIABILITY; DRUG SENSITIVITY; ENZYME STRUCTURE; EXPERIMENTAL STUDY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; STRUCTURAL PROTEOMICS; THEORETICAL STUDY; X RAY CRYSTALLOGRAPHY;

EID: 84928731157     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.02.009     Document Type: Article

References (65)

1. Andre F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., Shi M., Zhang Y., Kay A., Porta D.G., Yovine A., Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 2013, 19:3693-3702.
2. Ang D., Ballard M., Beadling C., Warrick A., Schilling A., O'Gara R., Pukay M., Neff T.L., West R.B., Corless C.L., Troxell M.L. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets. Diagn. Mol. Pathol. 2015, 23:97-103.
3. Azam M., Daley G.Q. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol. Diagn. Ther. 2006, 10:67-76.
4. Azam M., Seeliger M.A., Gray N.S., Kuriyan J., Daley G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 2008, 15:1109-1118.
5. Bae J.H., Boggon T.J., Tome F., Mandiyan V., Lax I., Schlessinger J. Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2866-2871.
6. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
7. Brooks A.N., Kilgour E., Smith P.D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. Cancer Res. 2012, 18:1855-1862.
8. Bussi G., Gervasio F.L., Laio A., Parrinello M. Free-energy landscape for beta hairpin folding from combined parallel tempering and metadynamics. J. Am. Chem. Soc. 2006, 128:13435-13441.
9. Byron S.A., Chen H., Wortmann A., Loch D., Gartside M.G., Dehkhoda F., Blais S.P., Neubert T.A., Mohammadi M., Pollock P.M. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 2013, 15:975-988.
10. Chell V., Balmanno K., Little A.S., Wilson M., Andrews S., Blockley L., Hampson M., Gavine P.R., Cook S.J. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013, 32:3059-3070.
11. Choi H.G., Ren P., Adrian F., Sun F., Lee H.S., Wang X., Ding Q., Zhang G., Xie Y., Zhang J., Liu Y., Tuntland T., Warmuth M., Manley P.W., Mestan J., Gray N.S., Sim T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J. Med. Chem. 2010, 53:5439-5448.
12. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., Ishikawa Y., Kimura H., Mitsudomi T., Tanio Y., Mano H., Group, A.L.K.L.C. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363:1734-1739.
13. Cools J., Deangelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348:1201-1214.
14. Crystal A.S., Shaw A.T., Sequist L.V., Friboulet L., Niederst M.J., Lockerman E.L., Frias R.L., Gainor J.F., Amzallag A., Greninger P., Lee D., Kalsy A., Gomez-Caraballo M., Elamine L., Howe E., Hur W., Lifshits E., Robinson H.E., Katayama R., Faber A.C., Awad M.M., Ramaswamy S., Mino-Kenudson M., Iafrate A.J., Benes C.H., Engelman J.A. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346:1480-1486.
15. Daub H., Specht K., Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 2004, 3:1001-1010.
16. Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013, 3:264-279.
17. Dutt A., Salvesen H.B., Chen T.H., Ramos A.H., Onofrio R.C., Hatton C., Nicoletti R., Winckler W., Grewal R., Hanna M., Wyhs N., Ziaugra L., Richter D.J., Trovik J., Engelsen I.B., Stefansson I.M., Fennell T., Cibulskis K., Zody M.C., Akslen L.A., Gabriel S., Wong K.K., Sellers W.R., Meyerson M., Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8713-8717.
18. Evans P.R., Murshudov G.N. How good are my data and what is the resolution?. Acta Crystallogr. D Biol. Crystallogr. 2013, 69:1204-1214.
19. Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 2006, 21:711-717.
20. Getlik M., Grutter C., Simard J.R., Kluter S., Rabiller M., Rode H.B., Robubi A., Rauh D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J. Med. Chem. 2009, 52:3915-3926.
21. Gibbons D.L., Pricl S., Kantarjian H., Cortes J., Quintas-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 2012, 118:293-299.
22. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
23. Gozgit J.M., Wong M.J., Moran L., Wardwell S., Mohemmad Q.K., Narasimhan N.I., Shakespeare W.C., Wang F., Clackson T., Rivera V.M. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012, 11:690-699.
24. Greulich H., Pollock P.M. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol. Med. 2011, 17:283-292.
25. Huang Z., Tan L., Wang H., Liu Y., Blais S., Deng J., Neubert T.A., Gray N.S., Li X., Mohammadi M. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem. Biol. 2015, 10:299-309.
26. Kabsch W. Processing of X-ray snapshots from crystals in random orientations. Acta Crystallogr. D Biol. Crystallogr. 2014, 70:2204-2216.
27. Kang Y.K., Yoo C., Ryoo B.Y., Lee J.J., Tan E., Park I., Park J.H., Choi Y.J., Jo J., Ryu J.S., Ryu M.H. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br. J. Cancer 2013, 109:2309-2315.
28. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
29. Konecny G.E., Kolarova T., O'Brien N.A., Winterhoff B., Yang G., Qi J., Qi Z., Venkatesan N., Ayala R., Luo T., Finn R.S., Kristof J., Galderisi C., Porta D.G., Anderson L., Shi M.M., Yovine A., Slamon D.J. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol. Cancer Ther. 2013, 12:632-642.
30. Lamont F.R., Tomlinson D.C., Cooper P.A., Shnyder S.D., Chester J.D., Knowles M.A. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 2011, 104:75-82.
31. Lei J., Li W., Yang Y., Lu Q., Zhang N., Bai G., Zhong D., Su K., Liu B., Li X., Wang Y., Wang X. TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074. PLoS One 2014, 9:e100075.
32. Liu L., Ye T.H., Han Y.P., Song H., Zhang Y.K., Xia Y., Wang N.Y., Xiong Y., Song X.J., Zhu Y.X., Li de L., Zeng J., Ran K., Peng C.T., Wei Y.Q., Yu L.T. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell. Physiol. Biochem. 2014, 33:633-645.
33. Lovera S., Sutto L., Boubeva R., Scapozza L., Dolker N., Gervasio F.L. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 2012, 134:2496-2499.
34. Mazzola C.R., Siddiqui K.M., Billia M., Chin J. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. Exp. Opin. Investig. Drugs 2014, 1-10.
35. Meharena H.S., Chang P., Keshwani M.M., Oruganty K., Nene A.K., Kannan N., Taylor S.S., Kornev A.P. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol. 2013, 11:e1001680.
36. Mohammadi M., Schlessinger J., Hubbard S.R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996, 86:577-587.
37. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., Eliseenkova A.V., Green D., Schlessinger J., Hubbard S.R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17:5896-5904.
38. Morrison J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185:269-286.
39. Motzer R.J., Porta C., Vogelzang N.J., Sternberg C.N., Szczylik C., Zolnierek J., Kollmannsberger C., Rha S.Y., Bjarnason G.A., Melichar B., De Giorgi U., Grunwald V., Davis I.D., Lee J.L., Esteban E., Urbanowitz G., Cai C., Squires M., Marker M., Shi M.M., Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:286-296.
40. Norman R.A., Schott A.K., Andrews D.M., Breed J., Foote K.M., Garner A.P., Ogg D., Orme J.P., Pink J.H., Roberts K., Rudge D.A., Thomas A.P., Leach A.G. Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J. Med. Chem. 2012, 55:5003-5012.
41. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., Metcalf C.A., Tyner J.W., Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., Wang Y., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W., Druker B.J., Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
42. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
43. Ramsey M.R., Wilson C., Ory B., Rothenberg S.M., Faquin W., Mills A.A., Ellisen L.W. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J. Clin. Invest. 2013, 123:3525-3538.
44. Renhowe P.A., Pecchi S., Shafer C.M., Machajewski T.D., Jazan E.M., Taylor C., Antonios-McCrea W., McBride C.M., Frazier K., Wiesmann M., Lapointe G.R., Feucht P.H., Warne R.L., Heise C.C., Menezes D., Aardalen K., Ye H., He M., Le V., Vora J., Jansen J.M., Wernette-Hammond M.E., Harris A.L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J. Med. Chem. 2009, 52:278-292.
45. Sabnis A.J., Bivona T.G. FGFR fusions in the driver's seat. Cancer Discov. 2013, 3:607-609.
46. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
47. Shan Y., Eastwood M.P., Zhang X., Kim E.T., Arkhipov A., Dror R.O., Jumper J., Kuriyan J., Shaw D.E. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012, 149:860-870.
48. Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 2012, 18:748-757.
49. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., Qiu K., Gao Z., Ceccarelli M., Riccardi R., Brat D.J., Guha A., Aldape K., Golfinos J.G., Zagzag D., Mikkelsen T., Finocchiaro G., Lasorella A., Rabadan R., Iavarone A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
50. Sutto L., Gervasio F.L. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10616-10621.
51. Tamborini E., Pricl S., Negri T., Lagonigro M.S., Miselli F., Greco A., Gronchi A., Casali P.G., Ferrone M., Fermeglia M., Carbone A., Pierotti M.A., Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006, 25:6140-6146.
52. Tan L., Wang J., Tanizaki J., Huang Z., Aref A.R., Rusan M., Zhu S.J., Zhang Y., Ercan D., Liao R.G., Capelletti M., Zhou W., Hur W., Kim N., Sim T., Gaudet S., Barbie D.A., Yeh J.R., Yun C.H., Hammerman P.S., Mohammadi M., Janne P.A., Gray N.S. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4869-E4877.
53. Taylor J.G.T., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., Yu Y., Chen Q.R., Shah K., Youngblood V., Fang J., Kim S.Y., Yeung C., Helman L.J., Mendoza A., Ngo V., Staudt L.M., Wei J.S., Khanna C., Catchpoole D., Qualman S.J., Hewitt S.M., Merlino G., Chanock S.J., Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
54. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
55. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70:2085-2094.
56. Wan S., Coveney P.V. Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs. J. R. Soc. Interface 2011, 8:1114-1127.
57. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J. 2011, 437:199-213.
58. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 2013, 22:795-803.
59. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., Ribas A., Li J., Moffat J., Sutherlin D.P., Koeppen H., Merchant M., Neve R., Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
60. Winn M.D., Ballard C.C., Cowtan K.D., Dodson E.J., Emsley P., Evans P.R., Keegan R.M., Krissinel E.B., Leslie A.G., McCoy A., Mcnicholas S.J., Murshudov G.N., Pannu N.S., Potterton E.A., Powell H.R., Read R.J., Vagin A., Wilson K.S. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 2011, 67:235-242.
61. Winter G., Lobley C.M., Prince S.M. Decision making in xia2. Acta Crystallogr. D Biol. Crystallogr. 2013, 69:1260-1273.
62. Xie L., Su X., Zhang L., Yin X., Tang L., Zhang X., Xu Y., Gao Z., Liu K., Zhou M., Gao B., Shen D., Zhang L., Ji J., Gavine P.R., Zhang J., Kilgour E., Zhang X., Ji Q. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013, 19:2572-2583.
63. Ye T., Wei X., Yin T., Xia Y., Li D., Shao B., Song X., He S., Luo M., Gao X., He Z., Luo C., Xiong Y., Wang N., Zeng J., Zhao L., Shen G., Xie Y., Yu L., Wei Y. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res. Treat. 2014, 143:435-446.
64. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2070-2075.
65. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., Engen J.R., Wong K.K., Eck M.J., Gray N.S., Janne P.A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.